Rationally designed antibodies
CA 2436671 C · Owner: Alexion Pharmaceuticals, Inc. · Inventors: Bowdish, Katherine S.; Barbas-Frederickson, Shana; Renshaw, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Antibodies or fragments thereof having CDR regions replaced or fused with biologically active peptides are described. Flanking sequences may optionally be attached at one or both the carboxy-terminal and amino-terminal ends of the peptide in covalent association with adjacent framework regions. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 5, 2001 and granted February 3, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended December 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.